Research ExplorerPublicationsDonor lymphocyte infusion enhances remission status in patie...

Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma.

Standard

Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. / Kröger, N; Krüger, W; Renges, H; Zabelina, Tatjana; Stute, N; Jung, Roman; Wittkowsky, G; Kuse, R; Zander, A.

In: BRIT J HAEMATOL, Vol. 112, No. 2, 2, 2001, p. 421-423.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kröger, N, Krüger, W, Renges, H, Zabelina, T, Stute, N, Jung, R, Wittkowsky, G, Kuse, R & Zander, A 2001, 'Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma.', BRIT J HAEMATOL, vol. 112, no. 2, 2, pp. 421-423. <http://www.ncbi.nlm.nih.gov/pubmed/11167841?dopt=Citation>

APA

Kröger, N., Krüger, W., Renges, H., Zabelina, T., Stute, N., Jung, R., Wittkowsky, G., Kuse, R., & Zander, A. (2001). Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. BRIT J HAEMATOL, 112(2), 421-423. [2]. http://www.ncbi.nlm.nih.gov/pubmed/11167841?dopt=Citation

Vancouver

Kröger N, Krüger W, Renges H, Zabelina T, Stute N, Jung R et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. BRIT J HAEMATOL. 2001;112(2):421-423. 2.

Bibtex

@article{9339f15b5c5d4938bfab09763ce37d20,
title = "Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma.",
abstract = "Two patients with persistent disease after allografting for multiple myeloma received donor T-cell lymphocyte infusion (DLI) (1.5 x 10(8) and 7 x 10(7)) to induce a graft-vs.-myeloma effect for further tumour regression after withdrawal of immunosuppression. The interval between stem cell transplantation and DLI was 8 and 14 months respectively. Both patients converted from partial to complete remission, lasting 12+ and 28+ months. Immunofixation became negative after 3 and 4 months. The main toxicity was grade II and III acute graft-vs.-host disease (GvHD) and limited or extensive chronic GvHD in each patient. We conclude that DLI induced further tumour reduction in patients with persistent disease after allografting for multiple myeloma.",
author = "N Kr{\"o}ger and W Kr{\"u}ger and H Renges and Tatjana Zabelina and N Stute and Roman Jung and G Wittkowsky and R Kuse and A Zander",
year = "2001",
language = "Deutsch",
volume = "112",
pages = "421--423",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma.

AU - Kröger, N

AU - Krüger, W

AU - Renges, H

AU - Zabelina, Tatjana

AU - Stute, N

AU - Jung, Roman

AU - Wittkowsky, G

AU - Kuse, R

AU - Zander, A

PY - 2001

Y1 - 2001

N2 - Two patients with persistent disease after allografting for multiple myeloma received donor T-cell lymphocyte infusion (DLI) (1.5 x 10(8) and 7 x 10(7)) to induce a graft-vs.-myeloma effect for further tumour regression after withdrawal of immunosuppression. The interval between stem cell transplantation and DLI was 8 and 14 months respectively. Both patients converted from partial to complete remission, lasting 12+ and 28+ months. Immunofixation became negative after 3 and 4 months. The main toxicity was grade II and III acute graft-vs.-host disease (GvHD) and limited or extensive chronic GvHD in each patient. We conclude that DLI induced further tumour reduction in patients with persistent disease after allografting for multiple myeloma.

AB - Two patients with persistent disease after allografting for multiple myeloma received donor T-cell lymphocyte infusion (DLI) (1.5 x 10(8) and 7 x 10(7)) to induce a graft-vs.-myeloma effect for further tumour regression after withdrawal of immunosuppression. The interval between stem cell transplantation and DLI was 8 and 14 months respectively. Both patients converted from partial to complete remission, lasting 12+ and 28+ months. Immunofixation became negative after 3 and 4 months. The main toxicity was grade II and III acute graft-vs.-host disease (GvHD) and limited or extensive chronic GvHD in each patient. We conclude that DLI induced further tumour reduction in patients with persistent disease after allografting for multiple myeloma.

M3 - SCORING: Zeitschriftenaufsatz

VL - 112

SP - 421

EP - 423

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 2

M1 - 2

ER -